Deng Yao, Zhang Ke, Tan Wenjie, Wang Yue, Chen Hong, Wu Xiaobing, Ruan Li
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Yingxin Street 100, Xuanwu District, Beijing 100052, People's Republic of China.
Vaccine. 2009 Mar 26;27(15):2085-8. doi: 10.1016/j.vaccine.2009.02.003. Epub 2009 Feb 12.
To explore the best prime-boost regimen and evaluate the T-cellular response memory against HCV, we constructed two DNA vaccine candidates (pVRC-CE1E2 and pAAV-CE1E2) and two recombinant viruses (rTTV-E1E2 and rAAV-E1E2) and then assessed the immune response to different prime-boost patterns in BALB/c mice. The rTTV-E1E2 boosted the immune response to HCV DNA vaccine prime significantly, and the inverted terminal repeat sequence harboring DNA construct PAAV-CE1E2 was the best prime agent in this study. Our study provides new information for both the prime-boost regimen and long-term T-cell response for HCV vaccine development.
为探索最佳的初免-加强免疫方案并评估针对丙型肝炎病毒（HCV）的T细胞应答记忆，我们构建了两种DNA候选疫苗（pVRC-CE1E2和pAAV-CE1E2）以及两种重组病毒（rTTV-E1E2和rAAV-E1E2），然后在BALB/c小鼠中评估了对不同初免-加强免疫模式的免疫应答。rTTV-E1E2显著增强了对HCV DNA疫苗初免的免疫应答，并且携带反向末端重复序列的DNA构建体PAAV-CE1E2是本研究中最佳的初免试剂。我们的研究为HCV疫苗开发的初免-加强免疫方案和长期T细胞应答提供了新信息。
